📊 AEON Key Takeaways
Is AEON Biopharma, Inc. (AEON) a Good Investment?
AEON exhibits critical balance sheet insolvency with negative stockholders equity of -$16.8M and total liabilities exceeding assets. Negative operating cash flow of -$2.6M combined with a current ratio of 0.99x indicates severe liquidity stress and an unsustainable burn rate, with only ~2-3 years of cash runway remaining.
AEON Biopharma's fundamentals are very weak: it appears to have no meaningful revenue base, continues to post operating and free cash flow losses, and carries negative stockholders' equity. With a current ratio below 1.0x and only $5.93M of cash against a $12.60M operating cash burn, the business looks dependent on external financing rather than internally generated growth.
AEON Biopharma, Inc. Key Strengths (AEON)
- Retains $6.2M in cash providing near-term operational buffer
- Minimal capital expenditure ($4K) suggests focus on asset-light development model
- Recent insider activity (5 Form 4 filings) indicates ongoing management engagement
- Cash and equivalents of $5.93M provide limited near-term liquidity
- Capital expenditure is minimal, indicating a relatively asset-light operating model
- Latest net loss of $2.08M was smaller than operating loss, suggesting some non-operating offset to core losses
AEON Stock Risks: AEON Biopharma, Inc. Investment Risks
- Negative stockholders equity of -$16.8M indicates technical insolvency and balance sheet failure
- Negative operating cash flow of -$2.6M with no revenue reported suggests unsustainable cash burn
- Current ratio of 0.99x reflects immediate liquidity crisis with current liabilities exceeding current assets
- Severe dilution risk from necessary capital raises to avoid bankruptcy
- Pre-revenue/early-stage development company with high probability of going concern failure
- No reported revenue or gross profit indicates an unproven commercial model
- Negative stockholders' equity of $19.87M and a 0.90x current ratio signal balance-sheet stress
- Operating cash flow and free cash flow of negative $12.60M imply ongoing cash burn and likely financing needs
Key Metrics to Watch
- Stockholders equity trajectory and path to positive equity
- Operating cash flow and burn rate relative to cash reserves
- Current ratio and working capital adequacy
- Revenue recognition from any clinical or commercial progress
- Capital raise announcements and dilution impact on shareholder equity
- Quarterly cash burn versus cash balance
- Any sustained revenue generation and improvement in working capital
AEON Biopharma, Inc. (AEON) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
AEON Profit Margin, ROE & Profitability Analysis
AEON vs Healthcare Sector: How AEON Biopharma, Inc. Compares
How AEON Biopharma, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is AEON Biopharma, Inc. Stock Overvalued? AEON Valuation Analysis 2026
Based on fundamental analysis, AEON Biopharma, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
AEON Biopharma, Inc. Balance Sheet: AEON Debt, Cash & Liquidity
AEON Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: AEON Biopharma, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $72.93 reflects profitable operations.
AEON Revenue Growth, EPS Growth & YoY Performance
AEON Biopharma, Inc. Dividends, Buybacks & Capital Allocation
AEON SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for AEON Biopharma, Inc. (CIK: 0001837607)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AEON
What is the AI rating for AEON?
AEON Biopharma, Inc. (AEON) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AEON's key strengths?
Claude: Retains $6.2M in cash providing near-term operational buffer. Minimal capital expenditure ($4K) suggests focus on asset-light development model. ChatGPT: Cash and equivalents of $5.93M provide limited near-term liquidity. Capital expenditure is minimal, indicating a relatively asset-light operating model.
What are the risks of investing in AEON?
Claude: Negative stockholders equity of -$16.8M indicates technical insolvency and balance sheet failure. Negative operating cash flow of -$2.6M with no revenue reported suggests unsustainable cash burn. ChatGPT: No reported revenue or gross profit indicates an unproven commercial model. Negative stockholders' equity of $19.87M and a 0.90x current ratio signal balance-sheet stress.
What is AEON's revenue and growth?
AEON Biopharma, Inc. reported revenue of N/A.
Does AEON pay dividends?
AEON Biopharma, Inc. does not currently pay dividends.
Where can I find AEON SEC filings?
Official SEC filings for AEON Biopharma, Inc. (CIK: 0001837607) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AEON's EPS?
AEON Biopharma, Inc. has a diluted EPS of $-0.29.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is AEON's fundamental grade?
Based on our AI fundamental analysis in June 2026, AEON Biopharma, Inc. has a D grade with 88% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is AEON stock overvalued or undervalued?
Valuation metrics for AEON: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is AEON's AI grade for 2026?
Our dual AI analysis gives AEON Biopharma, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AEON's free cash flow?
AEON Biopharma, Inc.'s operating cash flow is $-2.6M, with capital expenditures of $4.0K.
How does AEON compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.99 (avg: 2).